Nurse Practitioner Program year 2023 Reported 2022–2023 Source: CMS Open Payments, 2026 publication

Michele Hodges

Nurse Practitioner, Primary Care Mechanicsville, VA Nurse Practitioner

NPI 1962061101 CMS profile 10648838

7041 Lee Park Rd, Mechanicsville, VA 23111

Open in the dashboard

General payments

$1,245

69 records reported · program years 2022–2023

Research payments

$0

Paid to them · None reported · program years 2022–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Michele Hodges of Mechanicsville, VA is reported in the CMS Open Payments database as having received $1,245 across 69 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $1,228 68
2022 General $17 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michele Hodges
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Michele Hodges were reported at $0. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Michele Hodges Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $137 $39–$445 $132
2022 $17 $139 $44–$421 $149
2023 $1,228 $163 $53–$481 $160
2024 $0 $176 $54–$511 $164
2025 $0 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2022–2023
  1. Novo Nordisk Inc $281 17 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $225 8 payments
  3. AbbVie, Inc. $139 10 payments
  4. Amgen Inc. $139 10 payments
  5. Lilly USA, LLC $114 6 payments
  6. Otsuka America Pharmaceutical, Inc. $80 4 payments
  7. Janssen Pharmaceuticals, Inc $34 2 payments
  8. LifeScan, Inc. $31 1 payment
  9. GlaxoSmithKline, LLC. $27 2 payments
  10. Xeris Pharmaceuticals, Inc. $25 1 payment
  11. Other $151 8 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2023
  1. Food and Beverage $1,245 69 payments
Products named General payments · program years 2022–2023
  1. Kerendia $225 8 payments
  2. Ozempic $177 10 payments
  3. RYBELSUS $158 9 payments
  4. MOUNJARO $81 4 payments
  5. REXULTI $80 4 payments
  6. UBRELVY $72 4 payments
  7. Repatha $70 5 payments
  8. VRAYLAR $68 6 payments
  9. TRULICITY $58 3 payments
  10. EVENITY $56 4 payments
  11. Other $466 27 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 58 drugs

Part D claims

2,302

Median for Nurse Practitioner: 389

Drug cost

$110,371

Median for Nurse Practitioner: $21,885

Branded share of claims

23.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 41 $35,913
Eliquis Apixaban Brand 26 $18,725
Ozempic Semaglutide Brand 11 $14,241
Praluent Pen Alirocumab Brand 16 $8,789
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 248 $6,676
Oxycodone Hcl Generic 186 $3,058
Lidocaine Generic 30 $2,763
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 145 $2,638
Pregabalin Generic 84 $1,923
Gabapentin Generic 173 $1,735

The 10 drugs with the highest cost, of 58 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$1,659

Medicare's payments for the services billed

Medicare patients

37

Average age 73

Services billed

52

23 women, 14 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Chronic kidney disease 46%
Ischemic heart disease 43%
Diabetes 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

69 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record